Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.

Abstract:

INTRODUCTION:Patisiran and inotersen are two therapies approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, a rapidly progressive disease with a substantial clinical burden. This analysis indirectly compares the efficacy of patisiran and inotersen on neuropathy and quality of life (QOL). METHODS:Published results from the NEURO-TTR study of inotersen and individual patient data from the APOLLO study of patisiran were used. Indirect comparisons were conducted for 15-month changes in neuropathy and QOL endpoints: modified Neuropathy Impairment Score +7 (mNIS+7Ionis,), Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire, body mass index (BMI), and Polyneuropathy Disability (PND) score. Analyses were conducted under different assumptions about the impact of missing data and to adjust for baseline differences between studies. RESULTS:Patisiran showed significantly greater treatment effects than inotersen for mNIS+7Ionis (mean difference: -12.3 [95% confidence interval: -21.4, -3.3]), Norfolk QOL-DN (-11.3 [-19.8, -2.9]), and BMI (1.0 [0.4, 1.7]). The proportion of patients with improvement or no change from baseline on PND score was higher for patisiran-treated patients (odds ratio: 8.9 [4.6, 17.5]). Results were consistent and robust across analyses and methods. CONCLUSIONS:Patisiran demonstrated greater treatment effects on neuropathy and QOL than inotersen in patients with hATTR amyloidosis with polyneuropathy.

authors

Gorevic P,Franklin J,Chen J,Sajeev G,Wang JCH,Lin H

doi

10.1080/14656566.2020.1811850

subject

Has Abstract

pub_date

2021-01-01 00:00:00

pages

121-129

issue

1

eissn

1465-6566

issn

1744-7666

journal_volume

22

pub_type

杂志文章
  • Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention.

    abstract::Clopidogrel has become a mainstay in the management of acute coronary syndrome patients over the past decade, as well as an essential component of percutaneous coronary intervention (PCI) pharmacotherapy. Until recently, no prospective study has evaluated the effectiveness of clopidogrel in the setting of an ST-segmen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.12.1669

    authors: Hamdalla H,Moliterno DJ

    更新日期:2006-08-01 00:00:00

  • From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study.

    abstract:PURPOSE:To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). METHODS:Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1517/14656566.2011.589384

    authors: Rossi GC,Pasinetti GM,Sandolo F,Bordin M,Bianchi PE

    更新日期:2011-11-01 00:00:00

  • Safe Therapeutic Economic Pharmaceutical Selection (STEPS): development, introduction and use in Northern Ireland.

    abstract::A number of medicine selection methods have been used worldwide for formulary purposes. In Northern Ireland, integrated medicines management is being developed, and related projects have been carried out. This paper deals with the description of the STEPS (Safe Therapeutic Economic Pharmaceutical Selection) programme....

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.8.s1.s57

    authors: Scott M,Timoney M,Mairs J,Crealey G,Al Abaddi I,Brenninkmeijer R,Janknegt R,McElnay J

    更新日期:2007-10-01 00:00:00

  • An economic commentary on the occurrence and control of HIV/AIDS in developing countries: special reference to India.

    abstract::HIV infection has a complex relationship with poverty, but affects both the rich and poor. HIV/AIDS represents the deadliest emergency and the greatest social, economic and health crisis of modern times. The HIV pandemic affects developed and developing countries differently, with up to 95% of new HIV infections now o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.7.18.2447

    authors: Muniyandi M,Ramachandran R,Balasubramanian R

    更新日期:2006-12-01 00:00:00

  • Management of incomplete remission and treatment resistance in first-episode psychosis.

    abstract:BACKGROUND:Incomplete remission and treatment resistance are common even in first-episode psychosis patients. OBJECTIVE:The aim of this review was to provide an overview of the available interventions and treatment pathways for the management of incomplete remission and treatment resistance in first-episode psychosis....

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.12.2039

    authors: Lambert M,Naber D,Huber CG

    更新日期:2008-08-01 00:00:00

  • Metabolic syndrome management.

    abstract::Overweight, obesity and the metabolic syndrome occur in genetically susceptible individuals with environmental influences, and may be further compounded by other disorders of metabolism or pharmacological therapy that increase insulin resistance or promotes weight gain. Treatment of the metabolic syndrome should focus...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.13.2059

    authors: Stone NJ,Schmeltz LR

    更新日期:2007-09-01 00:00:00

  • Ras/Raf signalling and emerging pharmacotherapeutic targets.

    abstract::The Ras-Raf-MEK-ERK pathway is a ubiquitously expressed signalling module that regulates the proliferation, differentiation and survival of cells. This pathway features several oncogenes and is deregulated in approximately 30% of all human cancers. Thus, it has emerged as a prime target for antitumour therapy. Drugs t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.6.709

    authors: Kolch W

    更新日期:2002-06-01 00:00:00

  • Recent important trials of pharmacotherapy in Parkinson's disease.

    abstract::Parkinson's disease (PD) affects approximately 1% of individuals > 60 years. Of these PD patients approximately 40% suffer dementia in later life. Levodopa is commonly used in the treatment of PD. Experimental evidence suggests that the dopamine synthesised from levodopa may contribute to the further degeneration of d...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.6.1025

    authors: Doggrell SA

    更新日期:2005-06-01 00:00:00

  • Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer.

    abstract:INTRODUCTION:Breast cancer (BC) remains the most frequently diagnosed cancer and the most common cause of cancer death among women of all races worldwide. Over 80% of BC cases are hormone receptor (HR)-positive, comprised of luminal A and luminal B per molecular subtypes, imposing an urgent need to fully understand the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1429407

    authors: Duso BA,Trapani D,Viale G,Criscitiello C,D'Amico P,Belli C,Mazzarella L,Locatelli M,Minchella I,Curigliano G

    更新日期:2018-02-01 00:00:00

  • Advances in pharmacotherapy for hyperphosphatemia in renal disease.

    abstract:INTRODUCTION:Hyperphosphatemia in chronic kidney disease (CKD) is considered as an independent risk factor for surrogate clinical end points like vascular calcification (VC) and bone disease, or hard clinical outcomes like cardiovascular events. Various treatment options are available for phosphate removal or reduction...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1092521

    authors: Spasovski G

    更新日期:2015-01-01 00:00:00

  • Pharmacological management of human respiratory syncytial virus infection.

    abstract:INTRODUCTION:Human respiratory syncytial virus (hRSV) is the primary viral cause of respiratory diseases, leading to bronchiolitis and pneumonia in vulnerable populations. The only current treatment against this virus is palliative, and no efficient and specific vaccine against this pathogen is available. AREAS COVERE...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1806821

    authors: Kalergis AM,Soto JA,Gálvez NMS,Andrade CA,Fernandez A,Bohmwald K,Bueno SM

    更新日期:2020-12-01 00:00:00

  • Treating myoclonic epilepsy in children: state-of-the-art.

    abstract:INTRODUCTION:Myoclonic seizures can be observed in various clinical settings and different epileptic conditions, including some forms of both diopathic and symptomatic epilepsies. Relatively little has been written on treatment of myoclonic seizures. Some old antiepileptic drugs, such as valproate and some benzodiazepi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.800045

    authors: Striano P,Belcastro V

    更新日期:2013-07-01 00:00:00

  • Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

    abstract:INTRODUCTION:Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in tre...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1299710

    authors: Turner MC,Rossfeld K,Salama AK,Tyler D,Beasley G

    更新日期:2017-04-01 00:00:00

  • Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.

    abstract::Osteoporosis is a severe condition, associated with significant disability as a result of fragility fractures and increased mortality. Oral bisphosphonates effectively reduce the risk of osteoporotic fracture and are generally well tolerated. Unfortunately, patient outcomes are often compromised by suboptimal therapeu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.13.2301

    authors: Reginster JY

    更新日期:2005-10-01 00:00:00

  • Pharmacological treatment for uterine leiomyosarcomas.

    abstract:INTRODUCTION:Pharmacological treatment plays a major role in the management of advanced, persistent or recurrent uterine leiomyosarcoma (LMS), whereas its usefulness in the adjuvant setting is still debated. A thorough literature search was undertaken using the Pubmed databases. Systematic reviews and controlled trials...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.985205

    authors: Gadducci A,Guerrieri ME

    更新日期:2015-02-01 00:00:00

  • Aripiprazole for the treatment of irritability associated with autism.

    abstract:INTRODUCTION:Irritability (including tantrums, aggression and moodiness) is often associated with autistic disorder. Children with autism are frequently prescribed atypical antipsychotic medications for these behaviors. Although multiple agents have been found to be effective, the safety and tolerability of each antips...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.557661

    authors: Farmer CA,Aman MG

    更新日期:2011-03-01 00:00:00

  • Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.

    abstract::Introduction: Liposarcomas are a heterogeneous group of soft tissue tumors that arise from adipose tissue and are one of the most common soft tissue sarcomas found in adults. Liposarcomas are subclassified into four subtypes with distinct histologic and biologic features that influence their treatment and management. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1618271

    authors: Suarez-Kelly LP,Baldi GG,Gronchi A

    更新日期:2019-08-01 00:00:00

  • Adjunctive strategies in the treatment of refractory bipolar depression: clinician options in the absence of a systematic database.

    abstract::Multiple approaches to enhancing antidepressant treatment response in bipolar depression are available and should, in many instances, be explored despite a lack of definitive controlled trial literature supporting their efficacy. Given that the morbidity of depression is three times greater than mania in bipolar illne...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.4.531

    authors: Post RM

    更新日期:2005-04-01 00:00:00

  • Pharmacological treatment options for panic disorder in children and adolescents.

    abstract::Although panic disorder usually emerges in early to middle adulthood, adults with panic disorder often retrospectively report that their panic symptoms began in childhood or early adolescence. The majority of these juvenile cases are being misdiagnosed, and/or do not come to clinical attention. Awareness of early-onse...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.5.545

    authors: Masi G,Pari C,Millepiedi S

    更新日期:2006-04-01 00:00:00

  • Daily versus intermittent corticosteroids for the treatment of mild persistent asthma.

    abstract::Asthma is a chronic disease of the airways in which inflammation causes bronchial hyper-reactivity and attacks of wheezing, dyspnea and chest tightness that are triggered by various agents. It requires both acute treatment of the paroxistical respiratory symptoms with reliever medications and maintenance treatment, wh...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.7.9.1235

    authors: Antoniu SA

    更新日期:2006-06-01 00:00:00

  • Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.

    abstract:INTRODUCTION:The introduction of novel agents has significantly improved multiple myeloma (MM) patient outcome during the last two decades. MM received the most drug approvals for any one malignancy during this time period, both in the United States as well as in Europe. Areas covered: Proteasome inhibitors, immunomodu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1340942

    authors: Podar K,Pecherstorfer M

    更新日期:2017-08-01 00:00:00

  • Treatment options for lysosomal storage disorders: developing insights.

    abstract:INTRODUCTION:Lysosomal storage disorders (LSDs) are clinically heterogeneous disorders that result primarily from lysosomal accumulation of macromolecules in various tissues. LSDs are always progressive, and often lead to severe symptoms and premature death. The identification of the underlying genetic and enzymatic de...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.729039

    authors: van Gelder CM,Vollebregt AA,Plug I,van der Ploeg AT,Reuser AJ

    更新日期:2012-11-01 00:00:00

  • Ribavirin--current status of a broad spectrum antiviral agent.

    abstract::Ribavirin is a very broad-spectrum virustatic antiviral agent, first synthesised in 1972. It is characterised by low toxicity apart from reversible anaemia, usually mild. Its multiple mechanisms of action mean that viral resistance rarely develops. It can be administered orally, intravenously, or via a nebuliser. It h...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.8.1317

    authors: Snell NJ

    更新日期:2001-08-01 00:00:00

  • An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes.

    abstract:INTRODUCTION:The majority of patients with type 1 diabetes mellitus (T1DM) do not achieve glycemic targets. In addition, treatment with insulin is associated with increased risk for hypoglycemia and weight gain. Accordingly, there is an unmet need for new safe and effective glucose-lowering agents in this population. S...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1793961

    authors: Chatzopoulos G,Tziomalos K

    更新日期:2020-10-01 00:00:00

  • Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism.

    abstract:INTRODUCTION:Dementia with Lewy bodies (DLB) has no approved symptomatic or disease-modifying treatments in the US and Europe, despite being the second most common cause of neurodegenerative dementia. AREAS COVERED:Herein, the authors briefly review the DLB drug development pipeline, providing a summary of the current...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1828350

    authors: Panza F,Lozupone M,Watling M,Imbimbo BP

    更新日期:2020-10-06 00:00:00

  • Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.

    abstract:OBJECTIVE:To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since diagnosis as recently diagnosed (≤3 years) or chronic patients (>3 years). RESEARCH DESIGN AND METHODS:Post hoc analysis o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究

    doi:10.1080/14656566.2016.1174692

    authors: Hargarter L,Bergmans P,Cherubin P,Keim S,Conca A,Serrano-Blanco A,Bitter I,Bilanakis N,Schreiner A

    更新日期:2016-06-01 00:00:00

  • Second line treatment options for pancreatic cancer.

    abstract:INTRODUCTION:Patients with advanced pancreatic cancer (APC) refractory to first-line therapy have a dismal prognosis and limited therapeutic options, with only one option consisting of nanoliposomal irinotecan in combination with fluorouracil and folinic acid which was approved by FDA based upon results of the phase II...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1369955

    authors: Passero FC Jr,Saif MW

    更新日期:2017-10-01 00:00:00

  • Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients.

    abstract:INTRODUCTION:Antifungal resistance is an emerging problem that increases morbidity and mortality in immunosuppressed pediatric patients, who suffer from invasive fungal diseases. Optimal pharmacological management is critical for the successful treatment of invasive fungal infections by resistant strains. AREAS COVERE...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1000302

    authors: Stergiopoulou T,Walsh TJ

    更新日期:2015-02-01 00:00:00

  • Treating short bowel syndrome with pharmacotherapy.

    abstract:INTRODUCTION:Short bowel syndrome (SBS) has traditionally been regarded as a rapidly fatal medical catastrophe. The advent of pharmacological options directly targeting disease pathophysiology justified this review. AREAS COVERED:Since the 1970s, home parenteral nutrition has reduced mortality, converting SBS into a c...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1724959

    authors: Hollanda Martins Da Rocha M,Lee ADW,Marin MLM,Faintuch S,Mishaly A,Faintuch J

    更新日期:2020-04-01 00:00:00

  • Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.

    abstract:INTRODUCTION:Hepatitis C is a disease with a significant global impact. Over the last several years, the treatment of the disease has been revolutionized. Therapy has transformed over the last several years with the approval of second generation direct acting antivirals, and currently utilized medications for the treat...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1459567

    authors: Cory TJ,Mu Y,Gong Y,Kodidela S,Kumar S

    更新日期:2018-05-01 00:00:00